Online, usually BPC-157 together with TB-500 — but some media and research coverage uses 'Wolverine peptide' for BPC-157 on its own.
What the name is used to mean
- In research-market listings and forum posts, 'Wolverine' or 'Wolverine stack' almost always means BPC-157 plus TB-500 in one vial or taken together.
- Separately, media headlines and some research write-ups call BPC-157 by itself the 'Wolverine peptide'. The Registry does not treat those two meanings as the same thing, because one is a single compound and the other is a mixture.
- The reading is entrenched enough to be predictable, but it is still informal: no standards body, pharmacopoeia or regulator defines it, and nothing about the name tells you what material was used or how much of each is present.
- TB-500 adds a second layer of ambiguity. Material sold under that name may be a thymosin beta-4 fragment rather than full-length thymosin beta-4, and studies of one do not automatically apply to the other.
Documented readings of the name
BPC-157 + TB-500 (the usual online reading)
The most commonly described reading in research-market listings and community discussion. Recorded as what the name is used to mean, not as a validated formulation.
BPC-157 alone ('Wolverine peptide' in media coverage)
Seen in headlines and general coverage. This is a single compound with its own profile, not a mixture.
Combination evidence: No controlled human trial of this combination, as a combination, was identified in the curated record. The curated marketed-mixture record sits at evidence level 0 despite a 2026 exploratory rat combination study; that study does not establish human efficacy or safety, and the evidence positions of BPC-157 and TB-500 as individual compounds do not transfer to the mixture.
Read this first: Check which meaning is being used before reading anything into a claim about 'Wolverine'. Evidence about BPC-157 on its own is not evidence about a two-ingredient vial, and the reverse is also true.
Sources and review date
Last reviewed 2026-09-22
- Rising use of unapproved BPC-157 ('Wolverine Peptide') and associated patient-reported outcomes curated from clinical notes (preprint, posted 7 September 2026)
- FDA — Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026
- No controlled human trial of this combination, as a combination, was identified in the curated record.